27277750|t|Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid - polymer hybrid nanoparticles and effects on glioblastoma cells
27277750|a|Combination therapy using anticancer drugs and nucleic acid is a more promising strategy to overcome multidrug resistance in cancer and to enhance apoptosis. In this study, lipid - polymer hybrid nanoparticles (LPNs), which contain both pemetrexed and miR-21 antisense oligonucleotide (anti-miR-21), have been developed for treatment of glioblastoma, the most aggressive type of brain tumor. Prepared LPNs have been well characterized by particle size distribution and zeta potential measurements, determination of encapsulation efficiency, and in vitro release experiments. Morphology of LPNs was determined by transmission electron microscopy. LPNs had a hydrodynamic size below 100 nm and exhibited sustained release of pemetrexed up to 10 h. Encapsulation of pemetrexed in LPNs increased cellular uptake from 6% to 78%. Results of confocal microscopy analysis have shown that co-delivery of anti-miR-21 significantly improved accumulation of LPNs in the nucleus of U87MG cells. Nevertheless, more effective cytotoxicity results could not be obtained due to low concentration of anti-miR-21, loaded in LPNs. We expect that the effective drug delivery systems can be obtained with higher concentration of anti-miR-21 for the treatment of glioblastoma.
27277750	15	25	pemetrexed	T103	UMLS:C0210657
27277750	30	62	miR-21 antisense oligonucleotide	T103	UMLS:C0079925
27277750	66	71	lipid	T103	UMLS:C0023779
27277750	74	81	polymer	T103	UMLS:C0032521
27277750	118	130	glioblastoma	T038	UMLS:C0017636
27277750	131	136	cells	T017	UMLS:C0007634
27277750	137	156	Combination therapy	T058	UMLS:C0009429
27277750	163	179	anticancer drugs	T103	UMLS:C0003392
27277750	184	196	nucleic acid	T103	UMLS:C0028606
27277750	262	268	cancer	T038	UMLS:C0027651
27277750	284	293	apoptosis	T038	UMLS:C0162638
27277750	303	308	study	T062	UMLS:C2603343
27277750	310	315	lipid	T103	UMLS:C0023779
27277750	318	325	polymer	T103	UMLS:C0032521
27277750	348	352	LPNs	T103	UMLS:C1713964
27277750	374	384	pemetrexed	T103	UMLS:C0210657
27277750	389	421	miR-21 antisense oligonucleotide	T103	UMLS:C0079925
27277750	423	434	anti-miR-21	T103	UMLS:C0079925
27277750	474	486	glioblastoma	T038	UMLS:C0017636
27277750	516	527	brain tumor	T038	UMLS:C0006118
27277750	538	542	LPNs	T103	UMLS:C1713964
27277750	691	710	release experiments	T062	UMLS:C0681814
27277750	726	730	LPNs	T103	UMLS:C1713964
27277750	749	781	transmission electron microscopy	T058	UMLS:C0678118
27277750	783	787	LPNs	T103	UMLS:C1713964
27277750	807	811	size	T082	UMLS:C0456389
27277750	860	870	pemetrexed	T103	UMLS:C0210657
27277750	900	910	pemetrexed	T103	UMLS:C0210657
27277750	914	918	LPNs	T103	UMLS:C1713964
27277750	929	944	cellular uptake	T038	UMLS:C0007613
27277750	972	1000	confocal microscopy analysis	T058	UMLS:C0242842
27277750	1032	1043	anti-miR-21	T103	UMLS:C0079925
27277750	1067	1079	accumulation	T033	UMLS:C4055506
27277750	1083	1087	LPNs	T103	UMLS:C1713964
27277750	1095	1102	nucleus	T017	UMLS:C0007610
27277750	1106	1117	U87MG cells	T017	UMLS:C0007634
27277750	1148	1160	cytotoxicity	T038	UMLS:C0596402
27277750	1219	1230	anti-miR-21	T103	UMLS:C0079925
27277750	1242	1246	LPNs	T103	UMLS:C1713964
27277750	1277	1298	drug delivery systems	T074	UMLS:C0085104
27277750	1344	1355	anti-miR-21	T103	UMLS:C0079925
27277750	1364	1373	treatment	T058	UMLS:C0087111
27277750	1377	1389	glioblastoma	T038	UMLS:C0017636